Mass Spectrometry Shared Resource

质谱共享资源

• 批准号: 10599169
• 负责人: RICHARD D SCHULICK
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-04 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10599169
• 关键词: Academia; Accounting; Address; Amines; Antibodies; Applications Grants; Biochemistry; Bioinformatics; Biological; Biomedical Research; Biometry; Biotechnology; Books; Budgets; COVID-19 pandemic; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cells; Clinical Investigator; Colorado; Communities; Complex; Computer Analysis; Consultations; Coupled; Data Analyses; Data Collection; Detection; Development; Discipline; Doctor of Philosophy; Education; Educational process of instructing; Elements; Ensure; Environment; Enzymes; Equipment; Erythrocytes; Experimental Designs; Extracellular Matrix Proteins; Fees; Flow Cytometry; Fostering; Funding; Future; Genomics; Grant; Growth; Homeostasis; Human; Human Resources; Inductively Coupled Plasma Mass Spectrometry; Industry; Institution; Iron; Isomerism; Journals; Leadership; Libraries; Malignant Neoplasms; Manuscripts; Mass Spectrum Analysis; Measurement; Mentors; Metabolic; Metabolic Marker; Metals; Methodology; Methods; Mission; Mitochondria; Modeling; Molecular; Molecular Genetics; Monitor; Mus; Nature; Oxidation-Reduction; Pathology; Peer Review; Peptides; Phenotype; Plasma; Population; Proteomics; Protocols documentation; Publications; Publishing; Research; Research Personnel; Resolution; Sampling; Science; Secure; Services; Stable Isotope Labeling; Students; Sulfur; System; Techniques; Technology; The University of Colorado Cancer Center; Trace Elements; Training; United States National Institutes of Health; Universities; analytical method; animal imaging; anticancer research; aptamer; crosslink; data dissemination; data integration; experience; in vivo; innovation; insight; instructor; instrument; instrumentation; interest; ion mobility; lipidomics; mass spectrometer; mass spectrometry shared resource; member; metabolic imaging; metabolomics; mid-career faculty; next generation; novel; operation; programs; protein biomarkers; rapid technique; screening; small molecule; stable isotope; symposium; tool; transcriptomics; tumor microenvironment

ABSTRACT Overview: Proteomics, metabolomics, and lipidomics are critically essential techniques in cancer research. The Mass Spectrometry Shared Resource (MSSR), presented as a new UCCC SR in this application, supports UCCC members by utilizing mass spectrometry technologies to characterize a wide range of molecules in cancer biology applications. Services and Expertise: The primary focus of the MSSR is to provide the equipment and staff expertise to support application of, and education in, a range of MS-based methods. The MSSR mission is supported by a highly knowledgeable staff with >80 years combined experience in analytical methods to support biomedical research. Equipment: The MSSR houses 10 mass spectrometers, enabling global and targeted analysis of simple to highly complex biological samples. Management: The MSSR is co-directed by Dr. K Hansen (THI), a biochemist and proteomics expert who leverages mass spectrometry studies to investigate the tumor microenvironment, and Dr. A D'Alessandro (MCO), a biochemist and metabolomics expert who leverages MS to study cellular reprogramming in cancer and red blood cells. MSSR managers Dr. J Reisz Haines and Dr. M Dzieciatkowska collectively have >40 years of experience in Mass Spectrometry in academia and industry. Use of Services: Since July 2016, the MSSR has supported 268 investigators, including 55 UCCC members, 42 investigators from other NCI cancer centers, 152 other academic researchers, and 19 researchers at biotech organizations. UCCC members from all four programs have used MSSR services accounting for 38% ($971K) of total revenues over the period ($2.6M) and resulting in 56 cancer-related publications. Operating Budget: In the proposed budget model, CCSG funding represents 13% of the total ($1.2M) with the remaining from user fees (72%) and institutional support (15%). Innovation and Developments: The MSSR continually innovates and expands services to address evolving user needs and new opportunities in biomolecule characterization. In the most recent funding period, the MSSR added new services (e.g., crosslinking MS, metabolic flux analysis on as few as 250 cells) and equipment (Orbitrap Fusion Lumos and an inductively coupled plasma [ICP] MS), established a library of standards to enable quantitative measurements, and rapidly implemented remote operation for all staffing to ensure uninterrupted service during the COVID-19 pandemic. Future Directions: The MSSR will continue to provide support for MS-based research by UCCC members through acquisition and deployment of cutting-edge equipment, development of new methods, and expansion of training. To remain competitive, we will: i) develop a high-throughput plasma proteomics platform, building upon our acquisition of a 4D MS system (Bruker timsTOF Pro) and ii) increase throughput capabilities with the purchase of an Orbitrap Exploris and at least one high-parameter MS system for proteomics.

摘要 概述：蛋白质组学、代谢组学和脂质组学是癌症研究中至关重要的技术。的 质谱共享资源（MSSR），在此应用程序中作为一个新的UCCC SR，支持UCCC 成员通过利用质谱技术来表征癌症中的广泛分子 生物学应用服务和专业知识：MSSR的主要重点是提供设备和 工作人员的专业知识，以支持应用和教育，一系列的MS为基础的方法。MSSR的使命是 由知识渊博的员工提供支持，他们在分析方法方面拥有超过80年的综合经验， 生物医学研究设备：MSSR拥有10台质谱仪，可实现全球和有针对性的 分析简单到高度复杂的生物样品。管理：MSSR由K博士共同指导 汉森（THI）是一位生物化学家和蛋白质组学专家，他利用质谱研究来研究 D 'Alessandro博士（MCO），一位生物化学家和代谢组学专家， MS研究癌症和红细胞中的细胞重编程。MSSR经理J Reisz Haines博士和Dr. M Dzieciatkowska在学术界和工业界拥有超过40年的质谱分析经验。 服务使用：自2016年7月以来，MSSR已支持268名研究人员，包括55名UCCC成员， 42名来自其他NCI癌症中心的研究人员，152名其他学术研究人员和19名生物技术研究人员 组织的来自所有四个项目的UCCC成员使用了MSSR服务，占38%（97.1万美元） 这一时期的总收入（260万美元），并导致56个癌症相关出版物。业务预算：在 在拟议的预算模式中，CCSG资金占总额的13%（120万美元），其余资金来自用户 费用（72%）和机构支助（15%）。创新与发展：MSSR不断创新 并扩展服务，以满足不断变化的用户需求和生物分子表征的新机会。在 在最近的资助期间，MSSR增加了新的服务（例如，交联MS，代谢通量分析 少至250个细胞）和设备（Orbitrap Fusion Lumos和电感耦合等离子体[ICP] MS）， 建立了一个标准库，以实现定量测量，并迅速实施了远程 所有员工的营运，以确保在COVID-19大流行期间服务不间断。未来发展方向： MSSR将继续通过收购为UCCC成员的MS研究提供支持， 部署尖端装备，开发新方法，扩大训练。保持 我们将：i）开发高通量血浆蛋白质组学平台， 4D MS系统（Bruker timsTOF Pro）和ii）通过购买Orbitrap提高吞吐能力 Exploris和至少一个用于蛋白质组学的高参数MS系统。